A cost-minimization analysis of a preventive testing strategy for relatives of patients with BRCA mutated ovarian cancer

Eugenio Di Brino, Matteo Ruggeri, Stefania Boccia, Nicoletta Cerana, Domenica Lorusso, Dario Sacchini, Antonella Savarese, Liliana Varesco, Americo Cicchetti

Research output: Contribution to journalArticlepeer-review


Purpose: This study aims to estimate the cost-minimization strategy of a preventive testing strategy destined to relatives of patients with BRCA mutated cancer versus a no test strategy in Italia. Methods: A BRCA testing pathway was designed by a panel of experts based on the MSTM Excel (2010) tool; the analysis was carried out considering the perspective of the Italian National Health Service. Two alternatives were considered: 1) preventive BRCA testing for relatives of patients affected by ovarian cancer carrying a BRCA1/BRCA2 mutation; 2) no test. Cost and effectiveness data, derived from literature and published sources validated by a Board of experts, were discounted using a discount factor equal to 3%. Probabilistic sensitivity analysis was performed. Results: Considering an average cost of therapy for breast and ovarian cancer major of (sic)90,000.00 per case, the economic impact related to the preventive testing strategy are equal to -(sic)17,814,767.25. The sensitivity analysis confirms these results in the totality of the simulations performed. Conclusions: Preventive genetic testing in relatives of patients affected by ovarian cancer is cost-effective and represents a sustainable cost for the National Healthcare System in Italia, also in the light of its reference values.
Original languageItalian
Pages (from-to)1-8
Number of pages8
JournalGlobal and Regional Health Technology Assessment
Issue number1
Publication statusPublished - 2020

Cite this